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Abstract
Background: Smad4 is a tumour suppressor frequently inactivated in pancreatic and colorectal
cancers. We have recently reported loss of Smad4 in every fourth carcinoma of the uterine cervix.
Smad4 transmits signals from the TGF-β superfamily of cytokines and functions as a versatile
transcriptional co-modulator. The prevailing view suggests that the tumour suppressor function of
Smad4 primarily resides in its capability to mediate TGF-β growth inhibitory responses. However,
accumulating evidence indicates, that the acquisition of TGF-β resistance and loss of Smad4 may be
independent events in the carcinogenic process. Through inducible reexpression of Smad4 in
cervical cancer cells we wished to shed more light on this issue and to identify target genes
implicated in Smad4 dependent tumor suppression.
Methods: Smad4-deficient human C4-II cervical carcinoma cells were used to establish inducible
Smad4 reexpression using the commercial Tet-on™ system (Clontech). The impact of Smad4
reexpression on cell growth was analysed in vitro and in vivo. Transcriptional responses were
assessed through profiling on cDNA macroarrays (Clontech) and validated through Northern
blotting.
Results: Clones were obtained that express Smad4 at widely varying levels from approximately
physiological to 50-fold overexpression. Smad4-mediated tumour suppression in vivo was apparent
at physiological expression levels as well as in Smad4 overexpressing clones. Smad4 reexpression
in a dose-dependent manner was associated with transcriptional induction of the extracellular
matrix-associated genes, BigH3, fibronectin and PAI-1, in response to TGF-β. Smad4-dependent
regulation of these secreted Smad4 targets is not restricted to cervical carcinoma cells and was
confirmed in pancreatic carcinoma cells reexpressing Smad4 after retroviral transduction and in a
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stable Smad4 knockdown model. On the other hand, the classical cell cycle-associated TGF-β
target genes, c-myc, p21 and p15, remained unaltered.
Conclusion: Our results show that Smad4-mediated tumour suppression in cervical cancer cells
is not due to restoration of TGF-β growth inhibitory responses. Rather, tumour cell-ECM
interactions may be more relevant for Smad4-mediated tumour suppression. C4-II cells with a high
level inducible Smad4 expression may serve as a model to indicate further Smad4 targets
responsive to diverse environmental stimuli operative in vivo.
Background
Smad4 is a tumour suppressor gene primarily known for
its frequent inactivation in gastrointestinal malignancies.
Loss of Smad4 occurs in one half of pancreatic adenocar-
cinomas [1], in one third of metastatic colorectal cancers
[2] and in every fourth carcinoma of the small intestine
[3]. We have recently reported that Smad4 is also impli-
cated in cervical carcinogenesis [4]. Four of 13 cervical
cancer cell lines displayed Smad4 deficiency due to inser-
tional inactivation or homozygous loss of 3' exons. Fur-
thermore, Smad4 expression was lost in 10 of 41 primary
squamous cervical carcinomas and reduced in 26 cases as
shown by immunohistochemistry, whereas all cervical
intraepithelial neoplasias (CIN) retained normal Smad4
expression levels.
Defining the mechanisms of Smad4 tumour suppressor
function and identifying Smad4 target genes is critical to
address its potential as a therapeutic or diagnostic target.
Smad4 is characterised as a transmitter of signals of the
TGF-β superfamily of cytokines. The founding member of
this family, TGF-β1, potently inhibits the growth of nor-
mal epithelial cells. Cancer cells typically have lost sensi-
tivity to TGF-β antiproliferative responses. When Smad4-
deficient tumours were first identified, it was assumed
that loss of TGF-β antiproliferative and proapoptotic
responses underlie the tumour suppressor function of
Smad4. However, during recent years it has become evi-
dent that the relationship of TGF-β and Smad4 is much
more complex [5-11]. Accumulating evidence from our
lab and others has suggested that Smad4 loss and TGF-β
resistance attainable via multiple molecular alterations
may be independent events.
Squamous cell carcinoma of the uterine cervix is typically
initiated through infection with high-risk human papillo-
mavirus types, in particular HPV16 and HPV18. The E6
and E7 viral proteins deregulate cell growth control
through inactivation of the p53 and pRB tumour suppres-
sor gene products. Again, the postulated association of
Smad4 loss with TGF-β resistance appears less clear. Only
few from the cervical carcinoma cell lines display some
residual TGF-β responsiveness, irrespective of their
Smad4-positive or Smad4-negative status [4]. Loss of
Smad4 is a late step in gastrointestinal [12,2,13] as well as
in cervical cancers [4], consistent with the hypothesis that
Smad4 may function as a suppressor of invasion. TGF-β,
in contrast, is characterised as a promoter of invasion in
late stages of carcinogenesis [5-11]. Stable reexpression of
Smad4 in colorectal and pancreatic carcinoma cells at
physiological levels was adequate to suppress tumour
growth in vivo, but did not restore TGF-β responsiveness
[14,15]. Rather, we have shown that Smad4 regulates an
angiogenic switch [15] and functions as a positive regula-
tor of the invasion suppressor gene, E-cadherin [16,17],
and of the heterotrimeric laminin-5 molecule, which is a
major basement membrane constituent [18].
These data show that cell culture models are suited to
investigate mechanisms underlying Smad4-mediated
tumour suppression. However, it has been argued that sta-
ble transfection of Smad4 might select for clones that are
resistant to the growth inhibitory function of Smad4 due
to defects downstream of Smad4. Thus, we decided to
generate stable transfectants from Smad4-deficient C4-II
cervical cancer cells conditionally expressing Smad4. We
have obtained clones with a range of expression levels for
Smad4, spanning no expression, physiological expression
and overexpression up to approximately 50-fold of the
physiological level. Reduction of tumour growth in nude
mice was observed in clones with either physiological or
high Smad4 expression levels. In contrast, cell growth in
vitro  was not affected, except in clones with very high
Smad4 overexpression. Resistance towards TGF-β-medi-
ated growth inhibition, as measured by response of cell-
cycle associated genes such as c-myc, p21 and p15, was
retained in clones expressing physiological and 50-fold
increased Smad4 levels.
We then used expression profiling to search for Smad4-
dependent target genes. This revealed three genes, namely
PAI-1, fibronectin and BigH3, which were induced in
response to TGF-β in high as well as in low Smad4-
expressing C4-II cells. Interestingly, all of these genes
encode secreted proteins presumably affecting tumour
matrix and stroma. It is notable that the basal expression
levels (and TGF-β response) of these genes were also
increased by Smad4 reexpression in Smad4-negative pan-
creatic carcinoma cell lines, and were reduced upon
Smad4 knockdown in Smad4-positive cells.BMC Cancer 2007, 7:209 http://www.biomedcentral.com/1471-2407/7/209
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Methods
Cell culture
C4-II cells were obtained from the American Type Culture
Collection (Rockville, MD, USA). Cells were maintained
in Dulbecco's modified Eagles Medium (DMEM) supple-
mented with antibiotics and 10% fetal calf serum (FCS)
(Gibco). As Smad4 deficiency has not previously been
reported for cervical carcinoma cells, we first checked the
identity of the cell line. C4-II cells contain integrated
HPV18 DNA. HPV18 specific transcripts were detected by
RT-PCR. In addition, Southern hybridization of C4-II
genomic DNA with an HPV18 specific probe yielded
restriction fragments, which are indicative and specific for
the HPV18 integration site in C4-II cells [4].
Constructs
The set of vectors for tetracycline-inducible transgene
expression were purchased from Clontech Laboratories.
The full-length coding sequence of DPC4/Smad4 was
derived from the pBK-DPC4 constitutive expression con-
struct [14]. The DPC4/Smad4 coding sequence was
inserted into the NheI/EcoRI sites of the pTRE-vector. The
construct was confirmed by direct sequencing
(Sequitherm Cycle Sequencing, Epicentre). All plasmids
used for transfections were CsCl2 purified followed by
proteinase K digestion, phenol extraction and precipita-
tion.
Smad4 reconstituted pancreatic carcinoma cells were gen-
erated by retroviral transduction. The stable knockdown
derivatives from human pancreatic carcinoma cell line,
Paca44, were established through transfection of an
siRNA construct kindly provided by F. Kanai [19,20].
Conditional Smad4 expression in C4-II cells
C4-II cells were stably transfected using a standard cal-
cium phosphate coprecipitation method [14] with the
pTet-on™ plasmid encoding the reverse transactivator and
the neomycin phosphotransferase gene. Transfectants
were selected in media with 2 × 10-4 g/ml G418 and single
colonies were isolated and expanded. Clones that showed
a low basal activity and high inducibility of the transacti-
vator in the presence of doxycycline were identified by
transient transfections with the TRE-luciferase reporter.
Transient transfections were carried out with DAC 30™
transfection reagent (Eurogentec) according to the manu-
facturer's instructions. Luciferase was determined using a
luciferase detection kit (Promega). Two clones displaying
approximately 5-fold (clone 28) and 10-fold (clone 18)
induced luciferase expression in transient assays were cho-
sen for the second round of transfections. The TRE-DPC4
plasmid was cotransfected with pTK-Hyg or pY3-Hyg plas-
mids coding for the hygromycin B resistance gene. Selec-
tion was carried out in media with 2 × 10-4 g/ml G418 and
15 × 10-5 g/ml hygromycin B, yielding a total of 49 clones.
Northern blot analysis
RNA was isolated by acid phenol extraction or using a
commercial kit (RNeasy; Qiagen). Northern blots and
hybridisations were performed as described [14]. Blots
were stripped and reprobed for GAPDH as a loading con-
trol.
Preparation of proteins and Western blot analysis
Cells were lysed in NP-40 lysis buffer (25 mM TrisHCl, pH
7.4, 0.5% NP-40, 100 mM NaCl, 1 mM EDTA) containing
a protease inhibitor cocktail (Roche) and 1 mM PMSF.
Protein lysates were subjected to standard SDS-PAGE and
immunoblot analysis was performed as described [14].
The blots were incubated with monoclonal antibodies
against Smad4 (anti-Smad4 B8; dilution 1:500, Santa
Cruz). Antibodies against phospho-Smad2 and Smad3
from Biomol were used at a 1:1000 dilution.
Transient transfection assays with p6SBE and p3TPlux 
reporter plasmids
The p3TP-Lux construct was a kind gift from J. Massagué
[21]. The SBE-Luc reporter construct was kindly provided
by B. Vogelstein [22]. C4-II cells were plated in 10 cm
dishes. One day before transfection, half of the cells were
treated with doxycycline (2 × 10-6 g/ml) to induce Smad4
expression. Twenty-four hours later, 105 cells per well
were plated in 24 well plates with or without doxycycline.
Using the effectene transfection protocol, the cells were
transfected with 2 × 10-5 g p6SBE-luc reporter plasmid
containing 6 Smad binding elements concatemerised in
front of the reporter promoter or with 2 × 10-5 g p3TPluc
reporter plasmid containing AP1 and PAI-1 promoter ele-
ments. Transfection efficiency was determined from
cotransfection of the β-gal reporter plasmid (4.5 × 10-5 g
per well). The transfection mixture was removed 24 h
later, and the medium was replaced with fresh medium
with or without TGF-β (5 × 10-9 g/ml). The luciferase and
galactosidase activities were measured after another 24
hours. All assays were done in triplicate.
Analysis of TGF-β responses in vitro
For in vitro growth analysis 2 × 105 cells were plated on 60
mm dishes in medium with 0.5% fetal calf serum with or
without 2 × 10-6 g/ml doxycycline. Two days after plating
medium was replaced with fresh medium with or without
5 × 10-9 g/ml recombinant transforming growth factor
beta 1 (R&D systems). Cell numbers were counted from
duplicate plates every 3 or 4 days. Alternatively the cell
cycle phase distribution was determined by flow cytome-
try after propidiumiodide incorporation.
For the analysis of endogenous transcriptional responses,
2 × 106 cells were plated on 60 mm dishes in standard
medium or in serum-reduced medium (0.5% fetal calf
serum) with or without doxycycline. TGF-β (5 × 10-9 g/ml)BMC Cancer 2007, 7:209 http://www.biomedcentral.com/1471-2407/7/209
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was added after 24 hours, and cells were harvested for
RNA preparations 1, 2, 4, 8 and 24 hours later. Where
indicated, cells were treated with cycloheximide solubi-
lised in 0.25% ethanol at a final concentration of 5 × 10-6
g/ml.
Tumour growth in nude mice
Suspensions of 5 × 106 cells in a volume of 0.1 ml of phos-
phate-buffered saline were injected subcutaneously into
the flanks of 6-week old female athymic nude mice (Balb/
c01aHsd-nu/nu). Smad4 expression was induced prior to
injection of the cells through incubation in standard
medium containing 2 × 10-6 g/ml doxycycline, 1 × 10-4 g/
ml G418 and 75 × 10-6 g/ml hygromycin B. To maintain
Smad4 induction in vivo, drinking water for nude mice
bearing doxycycline-induced cells was supplemented with
2 × 10-3 g/ml doxycycline hydrochloride (Sigma) and
2.5% sucrose. Tumour growth was assessed every 3 days,
and animals were sacrificed 2 weeks (clones 18-2 and
derivatives) and 4 weeks (clones 28 and derivatives) after
injection of the cells, when the largest tumour in the
group reached a diameter of 10 mm. Tumours were
excised, weighed and snap frozen. The tumour growth
assays were performed twice with 3 mice per cell clone
both with and without Smad4 expression. Statistical sig-
nificance of tumour growth suppression was calculated
using a t-test after Welch correction using Graph Pad
Prism 4 software.
Atlas hybridisation experiments
Macroarray hybridisation was performed on BD Clontech
ATLAS human 1.2 microarrays according to the manufac-
turer's instructions. We used 3 × 10-5 g total RNA from
TGF-β- and doxycycline-treated cells for each hybridisa-
tion. The hybridised filters were analysed by phosphoim-
aging, and signals were quantified using GenePixPro
software.
Statistics
Data are presented as the mean and standard deviation.
All experiments were done in triplicate and repeated at
least twice with similar results. The numbers of mice per
group are noted in the figure's legends. The two-tailed t-
test with Welch correction was used to compare the tumor
growth in nude mice. The p-values are indicated (signifi-
cance p < 0.05).
Results
C4-II cells conditionally expressing Smad4 in vitro and in 
vivo
We chose to make use of the tetracycline conditional
expression system using the original two-step protocol in
order to avoid counterselection of Smad4-reexpressing
clones due to putative growth inhibitory effects [23]. In a
first transfection round, the tetracycline-dependent
reverse transactivator was transferred and clones display-
ing inducible expression of a reporter gene under control
of a tetracycline response element (TRE) were identified in
transient transfections. Two „tet-on" clones, namely clone
18 and clone 28, were used in a second round of transfec-
tions with the TRE-Smad4 expression plasmid yielding a
total of 49 derivative clones. We used Northern blot anal-
ysis to screen all clones, and identified 15 clones with
inducible Smad4 expression and very low or absent back-
ground expression (examples are shown in Figure 1a).
The time-course of induced Smad4 expression was ana-
lysed in one clone, 18-2, with low Smad4 expression and
in one clone, 28-14, with high Smad4 expression. Smad4-
specific transcripts were detectable after 4 hours in clone
18-2, and as soon as 1–2 hours in clone 28-14. Maximal
levels were reached after 6–9 hours (Figure 1b). As
expected, Smad4 protein expression closely followed the
time-course of mRNA induction (Figure 1c). The titration
of RNA and protein revealed that the Smad4 expression
level in clone 18-2 was approximately in the physiological
range (similar to SW480 derivatives characterised in detail
previously [14]) and that clones 28-14 and 28-8 expressed
roughly 20- to 50-fold more Smad4 RNA and protein (Fig-
ure 1d, e). Thus, the inducible expression system allows
investigation of Smad4 effects exerted at "normal" levels
as well as upon strong overexpression.
C4-II cell growth in vitro and in vivo
We have shown previously that Smad4-deficient C4-II
cells do not respond to TGF-β [4]. This result was con-
firmed with the C4-II tet-on clones 18 and 28 (Figure 2a,
b). Smad4 is known to mediate TGF-β-induced growth
inhibition in normal epithelial cells. Thus, we wondered
if inducible Smad4 expression was adequate to restore
TGF-β responsiveness in these cells. Cell growth in stand-
ard medium was not affected by physiological Smad4
expression levels in clone 18-2, and addition of recom-
binant TGF-β did not exert a measurable effect (Figure 2a,
b). In contrast, growth of clones 28-8 and 28-14 was mod-
erately reduced in standard medium and upon long-term
incubation, nearly came to a halt in TGF-β-containing
medium (Figure 2b). Notably however, effects of TGF-β
on the cell cycle distribution were moderate in 28-8 cells
as compared to HaCaT cells, which served as a positive
control [24] (Figure 2c).
Next, we analysed effects of Smad4 on cell growth in vivo.
It has been shown previously, that expression of a trans-
gene under the control of a TRE can be induced and main-
tained in vivo in mice by the addition of doxycycline to the
drinking water [25]. To determine whether conditional
Smad4 expression is functional in vivo in C4-II cell clones
and is sufficient to mediate suppression of tumour
growth, Smad4 expression was induced in vitro in one halfBMC Cancer 2007, 7:209 http://www.biomedcentral.com/1471-2407/7/209
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Characterisation of inducible Smad4-reexpression in C4-II tet-on cell clones Figure 1
Characterisation of inducible Smad4-reexpression in C4-II tet-on cell clones. a) Northern blot showing Smad4-spe-
cific mRNA in a number of independent clones derived from tet-on clones 18 and 28. Exposure of the left and middle panel 
was for one day, exposure of the right panel was five days. b) Time course of Smad4-induction in the "low-expressor" clone 
18-2 and in the high-expressor clone 28-14 at the mRNA level. c) Time course of Smad4-induction in clones 18-2 and 28-14 at 
the protein level. d) Titration of Smad4-mRNA levels in clones 18-2 and 28-14 as compared to Smad4-reexpressing SW480 cell 
clones. The latter clones have previously been shown to express (sub-)physiological Smad4 levels. e) Titration of Smad4 pro-
tein levels in clones 18-2, 28-14 and 28-8.
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Cell growth of Smad4-reexpressing C4-II tet-on cell clones in vitro and in vivo Figure 2
Cell growth of Smad4-reexpressing C4-II tet-on cell clones in vitro and in vivo. Long-term growth curves of the tet-
on clones 18 and 28 and Smad4-reexpressing derivatives 18-2, 28-8 and 28-14 were established in doxycycline-containing 
media in the absence (a) and in the presence (b) of TGF-β. c) Short-term TGF-β effects on cell cycle distribution were assessed 
in the high-expressor clone 28-8 as compared to HaCaT cells used as a positive control. Bars show mean values +/- standard 
deviation from three cultures per cell line and condition in one experiment. Similar results were obtained in repeated experi-
ments. d) Cell growth in vivo was assessed by subcutaneous injection in nude mice. The open bars and hatched bars show the 
mean tumour mass +/- standard deviation of 6 tumours, each, after 2 (clones 18 und 18-2) or 4 (clones 28, 28-8 and 28-14) 
weeks of growth in mice that received drinking water without and with the addition of doxycycline. Statistical significance is 
indicated. Similar results were obtained in repeated experiments.
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of the cells by overnight incubation in doxycycline con-
taining media. Cells were subcutaneously injected into
the flanks of nude mice and doxycycline was added to the
drinking water of mice bearing the induced cells. Tet-on
clones 18 and 28 were included as controls and tumour
growth was scored twice a week (Figure 2d). Addition of
doxycycline to the drinking water did not affect tumour
growth from tet-on clones 18 and 28, ruling out unspe-
cific effects of the inducer. In contrast, mean tumour mass
was significantly reduced to less than half as compared to
the uninduced cells in the low expressor clone, 18-2, as
well as in the high expressor clones, 28-8 and 28-14. Low
and high Smad4 expression levels were retained in vivo, as
confirmed in Northern blots of tumour-derived mRNA
(data not shown). Thus, physiological Smad4 levels in
this cell model are adequate to significantly reduce tumor
growth.
TGF-β responses in Smad4-deficient and in Smad4-
reexpressing C4-II cells
The ability of Smad4 to mediate tumour suppression has
largely been attributed to its presumed role as a mediator
of TGF-β-induced growth inhibition. Our results do not
support this hypothesis. Restoration of some TGF-β
responsiveness was restricted to clones displaying 20- to
50-fold overexpression of Smad4, while physiological
Smad4 levels were capable of exerting a Smad4-mediated
reduction in tumour growth.
We, therefore, proceeded to characterise TGF-β responses
in Smad4-deficient C4-II cells and in their Smad4-reex-
pressing derivatives in more detail. As the activation of
TGF-β receptors might be limiting, we first analysed phos-
phorylation of receptor Smads, Smad2/3, in response to
the addition of recombinant TGF-β (Figure 3a). No con-
stitutive phosphorylation was observed, and phosphor-
ylation in response to TGF-β did not differ between
Smad4-deficient and Smad4-reexpressing clones. This
result differs somewhat from published data, where high
constitutive phosphorylation of receptor-Smads was
reported in Smad4-deficient pancreatic cancer cells [26].
Next, we tested responses of the p6SBE and the p3TPluc
promoter-reporter constructs frequently used to assess
TGF-β responsiveness. The p6SBE promoter, constructed
to reflect Smad-dependent transcriptional induction, con-
tains concatemerised SBE (Smad binding element) sites
[21,22]. As expected, luciferase activity of this promoter
was not induced in the absence of Smad4 expression, but
was strongly increased by a factor of 5–8 in Smad4-reex-
pressing clones (Figure 3b). The p3TPluc promoter is a
hybrid promoter carrying sequences derived from the
fibronectin and PAI-1 promoters optimised as an indica-
tor of TGF-β responses. Interestingly, this construct was
induced independently of Smad4 by TGF-β by a factor of
approximately 1.5-fold in the tet-on clones (Figure 3c). As
expected, all Smad4-reexpressing clones showed increased
TGF-β induction of luciferase activity. Notably, induction
levels in response to TGF-β using both constructs were
quite similar between clone 18-2 and high-expressor
clones, 28-8 and 28-14.
As Smad4 proved fully functional in transmitting TGF-β
responses in transient transfection assays, we then deter-
mined responses of endogenous TGF-β target genes (Fig-
ure 4). TGF-β-induced growth inhibition in normal
epithelial cells is associated with Smad4-dependent alter-
ations in cell cycle-associated target genes, namely the
transcriptional repression of c-myc and induction of p15
and p21 [27,28]. Minor effects on the levels of c-myc tran-
scripts were observed here, but were not dependent on
Restoration of TGF-β responses in Smad4-reexpressing C4-II  clones Figure 3
Restoration of TGF-β responses in Smad4-reexpress-
ing C4-II clones. a) Phosphorylation of R-Smad2/3 in 
response to TGF-β was assessed through Western blotting 
with a phospho-Smad2/3-specific antibody. b) TGF-β 
response in transient transfections with the p6SBE-luc pro-
moter; the induction factor in Smad4-reexpressing clones is 
5–8. c) TGF-β response in transient transfections with the 
p3TP-luc promoter; induction in Smad4-negative cells is 
approximately 1.5 and rises to 3–4 in Smad4-reexpressing 
clones.
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Smad4 expression. No changes in the levels of p15 and
p21 transcripts were detected (Figure 4). These results
show that reexpression of Smad4, even at much higher
levels, is not adequate to restore TGF-β-induced growth
inhibition through the classical pathway.
Smad4 effect on target genes encoding secreted proteins 
through indirect mechanisms
Smad4 target genes previously identified in colorectal and
pancreatic carcinoma cells, namely E-cadherin [16], lam-
inin-5 [18], VEGF and thrombospondin-1 [15], were not
affected through Smad4 reexpression in C4-II cervical can-
cer cells (data not shown). We used expression profiling
in order to detect alternative Smad4 target genes. Macroar-
rays were hybridised with cDNA derived from 18-2 cells
and from 28-8 cells cultured in the absence or presence of
doxycycline and untreated or treated with TGF-β. We
detected no significant differences in expression profiles
of 18-2 cells +/- doxycycline or +/- TGF-β. Likewise, 28-8
cells grown in standard media in the absence and presence
of doxycycline did not display Smad4 target genes. Ulti-
mately, hybridisation of cDNA derived from TGF-β-
treated 28-8 cells revealed Smad4-dependent TGF-β
induction of BigH3, fibronectin and PAI-1 (Figure 5a). It
is noteworthy to mention that all of these target genes
encode secreted and extracellular matrix-associated pro-
teins. Northern blotting with RNA prepared from all three
clones at different time points after TGF-β induction con-
firmed strong induction of these three target genes in the
high-expressor clones, 28-8 and 28-14 (Figure 5b). The
low expressor clone, 18-2, displayed significant but less-
pronounced increases in mRNA levels of the target genes
(Figure 5b). To examine if the effect was dose-dependent,
we titrated Smad4 levels in clone 28-8. Also in this clone,
low levels of Smad4 were sufficient to induce expression
of BigH3, fibronectin and PAI-1 in response to TGF-β, and
the extent of induction mounted in parallel with doxycy-
cline and corresponding Smad4 levels (Figure 5c).
It has been shown previously, that TGF-β induction of
fibronectin and PAI-1 can be mediated through a direct
mechanism via activation of receptor-Smads and binding
of heteromeric R-Smad/Smad4-complexes to SBE sites in
the promoter regions of the genes. Here, induction of the
three target genes was apparent only at late time points,
suggesting that it might work through indirect mecha-
nisms. In fact, cycloheximide treatment of the cells sup-
pressed induction to virtually basal levels (Figure 5d).
These results show that TGF-β induction of BigH3,
fibronectin and PAI-1 correlates with Smad4 expression
levels and works via indirect mechanisms requiring pro-
tein synthesis.
Smad4 control of secreted TGF-β target genes is not 
restricted to cervical cancer cells
In order to assess the scope of our findings we wished to
know if Smad4 controls the expression of secreted TGF-β
target genes in tumour cells derived from other organs.
Smad4 was reintroduced into the BxPC3 and Capan1 pan-
creatic carcinoma cell lines via retroviral transduction,
and led to approximately 3- to 5-fold Smad4 overexpres-
sion (data not shown).
Target gene analysis using Northern blotting revealed pro-
nounced differences in basal expression levels of fibronec-
tin and BigH3, and TGF-β, but all three target genes were
induced in a Smad4-dependent manner (Figure 6).
Northern blot analysis of endogenous TGF-β target genes Figure 4
Northern blot analysis of endogenous TGF-β target genes. Clones 18-2, 28-8 and 28-14 were cultured in the absence 
or presence of doxycycline and treated with TGF-β for the indicated periods of time. Equal loading was controlled by hybridi-
sation with a Gapdh probe.
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Identification and validation of Smad4-dependent TGF-β target genes Figure 5
Identification and validation of Smad4-dependent TGF-β target genes. a) Smad4-dependent TGF-β target genes in 
28-8 cells were identified through hybridisation of Clontech Cancer II arrays. At least three hybridisations were performed for 
each clone and each set of conditions. Shown as examples are sections of filters containing the probes for fibronectin and 
BigH3. The induction of PAI-1 was detectable but less clear because a very strong neighbouring signal faded over the PAI-1 
locus (data not shown). b) Corresponding filters to those shown in figure 4 were hybridised with probes for BigH3, fibronectin 
and PAI-1. c) Smad4-levels were titrated in clone 28-8 through dilution of doxycycline. Northern blotting with the same probes 
as used in (b). d) TGF-β induction of 28-8 cells was repeated in the presence of cycloheximide
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Lastly, we asked if Smad4 knockdown in Smad4 positive
cells also would return the transcript levels of the secreted
target genes to the basal level. To this aim we established
stable derivatives from the human pancreatic carcinoma
cell line, Paca44, via transfection of an siRNA construct
kindly provided by F. Kanai [19,20]. Smad4 was downreg-
ulated to < 10% of the endogenous level in the resulting
clones. Constitutive expression levels of BigH3 in Paca44
knockdown clones were significantly reduced (Figure 7).
In addition, clones with reduced Smad4 expression exhib-
ited reduced transcriptional responses to TGF-β (data not
shown). These results provide additional evidence that
Smad4 functions as a positive regulator of BigH3 expres-
sion in diverse cell types.
Analysis of secreted TGF-β target genes in Smad4-reexpressing pancreatic carcinoma cells Figure 6
Analysis of secreted TGF-β target genes in Smad4-reexpressing pancreatic carcinoma cells. Stable reexpression 
of Smad4 was established in BxPC3 and Capan1 human pancreatic carcinoma cells through retroviral transduction. Shown are 
endogenous expression levels of BigH3, fibronectin and PAI-1 in response to TGF-β treatment of, a representative Smad4-defi-
cient control clone and a Smad4-reexpressing clone from both cell lines.
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Discussion
Concurrent with the identification of Smad4 as a tumour
suppressor gene, the hypothesis was raised that loss of
TGF-β antiproliferative and proapoptotic responses
underlie the tumour suppressor function of Smad4. Stable
Smad4 reexpression in colorectal and pancreatic cancer
cells was adequate to mediate tumour suppression in vivo,
did not inhibit cell growth in vitro and was not sufficient
to rescue TGF-β antiproliferative responses. To rule out
that stable Smad4 expression may select for clones in
which TGF-β resistance is caused by additional defects
downstream of Smad4, we developed a cell model with
conditional Smad4 expression. We obtained clones using
a tet-on system in which Smad4 can be reversibly turned
off and on to levels ranging between zero and 50-fold of
endogenous levels in the control cells. Using this system,
we found that reduced tumour growth in vivo could be
mediated through physiological as well as excessive levels
of Smad4. In contrast, reduced cell growth in vitro and
growth inhibition in response to TGF-β were restricted to
cells strongly overexpressing Smad4. The "classical" cell
cycle-associated TGF-β target genes were, however, not
induced under these conditions, suggesting that growth
responses in these cells in vitro do not reflect physiological
mechanisms in cancer cells but occur only upon excessive
Smad4 overexpression.
To the best of our knowledge, the only conditional Smad4
expression model published to date was developed by
Calonge and Massagué [29]. These authors established
cell clones derived from the SW480 colorectal carcinoma
cell line using an ecdysone inducible system. They
obtained maximal Smad4 expression levels which were
comparable to endogenous levels expressed in HaCaT
control cells. Consistent with our previous results using
stable transfection of SW480 cells [14], conditional
Smad4 expression also did not affect the TGF-β target
genes, p21 and c-myc, and was not sufficient to restore
TGF-β-induced growth inhibition.
We conclude from our results that, as has previously been
shown for colorectal and pancreatic cancer cells [14,15],
direct effects of Smad4 on tumour cell proliferation in cer-
vical carcinoma cells are dispensable for Smad4-mediated
tumour suppression. These results strengthen the idea that
Smad4-dependent tumour suppression is due to more
complex mechanisms functioning in vivo, which may
include altered interactions of tumour cells with stromal
cell types and the extracellular matrix. Target genes
involved in the Smad4-mediated tumour suppression in
colorectal and in pancreatic carcinoma cells, such as E-
cadherin [16], laminin-5 [18], VEGF and thrombospon-
din-1 [15], however, did not respond to Smad4-reexpres-
sion in C4-II cervical cancer cells.
Expression profiling on macroarrays did not show altered
expression levels of Smad4 target genes without TGF-β
treatment of Smad4-expressing C4-II cells. After TGF-β
treatment, the Smad4 target genes, fibronectin, PAI-1 and
BigH3, were induced in C4-II cells expressing physiologi-
cal levels of Smad4 and superinduced in Smad4-overex-
pressing cells. Whereas Smad4-dependent TGF-β
induction of these genes is not novel [30-33], the under-
lying pathway appears to differ from that in normal epi-
thelial cells. The linear TGF-β/Smad pathway signals from
activated TGF-β receptors via phosphorylation of recep-
tor-Smads. This leads to complex formation with Smad4,
translocation of heteromeric Smad complexes into the
nucleus and binding to SBE sites in the promoter regions
of target genes. This direct pathway does not depend on
protein synthesis, and results in rapid transcriptional
induction. In Smad4-reexpressing C4-II cells, however,
induction of the target genes appeared late and was sup-
pressed to near basal expression levels by the addition of
cycloheximide. We conclude that this Smad4-mediated
induction requires protein synthesis, and may be executed
through Smad4 induction of other transcription factors
which in turn induce transcription of Smad4 target genes
in an indirect manner. We used transient transfections of
Analysis of BigH3 expression Figure 7
Analysis of BigH3 expression. Analysis of BigH3 expres-
sion in pancreatic carcinoma cells retaining endogenous 
Smad4 expression and upon stable Smad4-knockdown. 
RNAs from three independent Smad4-positive control 
clones and three knockdown clones, in which Smad4 expres-
sion was reduced to below 10% were hybridised with the 
BigH3 specific probe.
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promoter-reporter constructs in order to identify putative
transcription factor binding sites responsible for such
indirect Smad4 effects. However, luciferase reporter activ-
ity in transiently transfected C4-II cells with or without
doxycycline-induced Smad4 expression and with or with-
out TGF-β did not reflect the transcriptional responses of
the endogenous target genes. Unravelling the underlying
molecular mechanisms in detail will require more cum-
bersome approaches. As Smad4-expression in C4-II cells
can be tightly controlled, whole genome expression pro-
filing in time-course experiments may indicate direct and
indirect Smad4 target genes.
The three Smad4 target genes identified in C4-II cervical
cancer cells encode secreted proteins which are deposited
in extracellular matrices in tissues in vivo. It is well known,
that interactions between cells and extracellular matrix
(ECM) in general play a crucial role in tumour angiogen-
esis, invasiveness and metastasis [8,34]. Consequently,
the roles of ECM molecules have been addressed in
numerous studies. High expression levels of PAI-1, for
example, have been correlated with pro- and anti-tumour
effects. The reported prognostic relevance of PAI-1 in cer-
vical cancer as well as in other cancer types is conflicting
[35]. An expression analysis of BigH3 in cervical cancers
has not yet been published. Interestingly, the expression
levels of BigH3 in pancreatic carcinomas were reported to
be high, although highly variable, in virtually every sam-
ple analysed in one study [36]. It would be interesting to
correlate the Smad4 status of the tumour cells with TGF-β
and BigH3 levels in this tumour panel.
Recent approaches addressing functions of BigH3 in the
carcinogenic process have consistently suggested anti-
tumour activity, and have unravelled novel mechanisms
how this protein could exert tumour suppressive effects.
BigH3, also known as keratoepithelin and as TGF-β-
induced gene, is a ubiquitous constituent of the extracel-
lular matrix [33]. It encodes a 69 kDa protein containing
four internal fascilin I-like repeats (fas domains) and an
RGD peptide at the C-terminus. BigH3 supports cell
attachment and spreading, induces actin stress fiber for-
mation, and binds fibronectin [37] and integrins. Skonier
et al. have shown that BigH3 gene transfection into CHO
cells led to a marked decrease in the ability of these cells
to form tumours in nude mice [33]. Also, restoration of
BigH3 in human bronchial epithelial cells resulted in a
significant reduction in tumour growth [38,39]. BigH3
induced differentiation in keratinocytes [40] and inhib-
ited proliferation and invasion in human neuroblastoma
cells [41]. Interestingly, fastatin, the fourth FAS domain of
BigH3, has been shown to induce apoptosis and suppress
endothelial tube formation, thus inhibiting tumour
growth through suppression of neovascularisation
[42,43]. Although no reports concerning BigH3 functions
in cervical tissues exist to our knowledge, it is reasonable
to speculate that this protein may also exert anti-tumour
effects in cervical tumours.
Smad4 functions as an integrator of cellular responses to
multiple external stimuli. Consequently, the outcome of
Smad4 reexpression on expression profiles of tumour cells
in vivo will widely differ from expression patterns in vitro.
The microenvironment in vivo is regulated through com-
plex interactions between tumour and stromal cell types.
Growth factors and cytokines other than TGF-β may be
expressed either by the tumour cells, by activated fibrob-
lasts, or by inflammatory and immune cells. Treatment
with recombinant cytokines to mimic the effect of these
stromal cell types in vivo in combination with whole
genome expression profiling holds promise to discover
additional Smad4 target genes in the future. C4-II cells
conditionally expressing extensive Smad4 levels in such
approaches may serve as superindicators of cytokine-
induced Smad4-responsive genes.
Conclusion
The heterologous reexpression of Smad4 in Smad4-defi-
cient cancer cell lines could reduce tumor growth in vivo.
The expression of classical TGF-β target genes involved in
cell cycle regulation was not affected by Smad4 reexpres-
sion. Otherwise, Smad4 dose-dependently controls the
TGF-β induced expression of genes associated with extra-
cellular matrix. We conclude that Smad4 effects on the
composition of extracellular matrix may underlie its
tumor suppressive activity.
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